CALL FOR 2023 LETTERS OF INTENT

2023 grant process timeline:

• May 1 – May 30: LOI submissions
• June 1: RFA released on Curebound website and via email
• June 12 – August 1: Application portal open
• August 15 – October 15: Peer review process
• November 15: Grant winners selected no later than November 15
• December: Applicant teams notified and grant funding distributed

All project teams that apply for Curebound grant funding must have at least one lead investigator on staff at one of six research partner institutions.

• UC San Diego*
• Salk Institute
• Sanford Burnham Prebys
• Rady Children’s Hospital
• La Jolla Institute for Immunology
• Rady Children’s Hospital
• Scripps Research

*Includes UC San Diego Health and affiliated institutions i.e., Moores Cancer Center, San Diego State University, and J. Craig Venter Institute.

Proposals must align with at least one or more of the following Curebound Research Pillars to be funded:

• Prevention & Diagnostic Tools
• Cancer Equities
• Novel Therapeutics & Platforms
• Immunotherapies & Personalized Vaccines
• Pediatric Cancers

Will be considered for funding in the following three ways:

Discovery Grants: Curebound will fund seed grants for high-risk high-reward innovative, collaborative research. Discovery Grants are intended to fund early-stage ideas and recent breakthroughs from the investigators’ ongoing research accelerating them towards the clinic. Discovery Grants will prioritize research that advances therapeutic development and/or has a high likelihood of leveraging extramural funding. Inter-institutional collaboration is required, if you need help finding a collaborator with the right expertise send us an email at research@curebound.org

• $250,000 for a 1-year award inclusive of up to 30% IDC
• Applicants may add collaborators to fulfill this requirement after the submission of the LOI. If applicant fails to add a collaborator from a different institute Curebound will not review the proposal
• Applicants will be invited to apply for a Discovery grant based on review of submitted LOIs

Targeted Grants: Curebound will fund innovative, translational, oncology-based projects that show promise of advancing to pre-clinical or clinical stages. Priority will be given to applications that have a high likelihood of significantly advancing detection, prevention, therapeutic development, access to patient care and/or clinical trials. Targeted Grants will fund continuity of ideas from the investigators’ past research, including research that builds upon previously funded Discovery Grants or Pedal Pilot grants. Interdisciplinary collaboration is required and inter-institutional collaboration, while not required, is preferred.

• $500,000 for a 1 to 2-year award inclusive of up to 30% IDC
• Option to re-apply for subsequent years
• Applicants will be invited to apply for a Targeted grant based on review of submitted LOIs

Cure Prize: Curebound’s Scientific Board will award its prestigious annual Cure Prize to fund innovative ground-breaking ideas that change the course of cancer research and care. Cure Prizes will be awarded to teams who present collaborative and/or inter-disciplinary solutions that show near-term promise of clinical breakthrough and represent “game changers” in the prevention, diagnosis, access or treatment of cancer patients.

• $1,000,000 for a 2- to 3-year award (either $500,000/year for 2 years or $333,333/year for 3 years) inclusive of up to 30% IDC
• Applicants will be invited to apply for a Cure Prize based review of submitted LOIs by Curebound’s Scientific Advisory Board